Dr Reddy’s Laboratories expects to launch 25 products in the US market in the current financial year, according to a top company official. The drug major has also earmarked a capital expenditure (capex) of Rs 1,000 crore for finding various projects during the ongoing financial year.
“On a full-year basis (2019-20), we launched 27 products, including four re-launch of the earlier discontinued products. We expect the new launches momentum to continue during the year with about 25 product launches lined up despite uncertainty due to COVID-19,” Dr Reddy’s Laboratories CEO Erez Israeli said in an analyst call.
As of March 31, 2020, the company has 99 cumulative filings pending for approval with the US Food and Drug Administration (USFDA), including two new drug approvals (NDAs), he added.
“We also filed 59 drug master files globally, including seven filings made in the US,” Israeli said.
On new pipeline of products, he said the company is also working on a few molecules related to COVID-19.
Besides, the drug maker is also working on various biosimilar products, including, the Rituximab Phase III trial is progressing as per plan.
Jun 28, 2020